Lupin appoints Brian Savage as President and Chief Legal Officer

Compliance View source PDF Explain this filing

LUPIN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.4%Reaction day

₹1922.00

prior close

₹1903.90

announcement price

In-mkt

timing

Nifty Midcap 150market-2.1%+2.4% vs market

Pharmaceuticals peers, median of 170sector-1.6%+1.9% vs sector

On the reaction day the stock moved 2.4 pts more than Nifty Midcap 150 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

-0.2

15m

-0.2

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.4-2.1+2.4-1.6+1.9

Next day

+2.0-1.0+3.0-0.5+2.4

+1.6-0.1+1.7+1.5+0.0

+2.7pendingpending+2.5+0.2

—————

15d

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lupin appointed Brian Savage as President and Chief Legal Officer. He will lead the company's global legal, compliance and intellectual property teams from New Jersey. Savage joins from Teva Pharmaceuticals, where he has worked since 2015 and most recently served as Executive Vice President and interim global chief legal officer.

Likely market impact

No financial terms were disclosed. The role may strengthen legal and regulatory oversight, but no immediate earnings or share-price impact was stated.